Autolus Therapeutics plc (AUTL) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — AUTL

Balance Sheet

(in billions USD)

Metric	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q1 2021
Cash & Equivalents	0.13	0.09	0.12	0.10	0.66	0.71	0.76	0.26	0.24
Accounts Receivable	0.03	--	--	--	0.00	0.00	0.00	0.00	--
Inventory	0.03	0.03	0.02	0.01	--	--	--	--	--
Total Current Assets	0.37	0.51	0.57	0.62	0.72	0.76	0.80	0.31	0.29
Property, Plant & Equipment	0.06	0.07	0.07	0.06	0.04	0.03	0.03	0.03	0.03
Intangible Assets	0.02	0.02	0.01	0.01	--	--	--	--	0.00
Total Non-current Assets*	0.16	0.12	0.13	0.11	0.11	0.10	0.10	0.10	0.06
Total Assets	0.53	0.66	0.72	0.75	0.83	0.85	0.90	0.41	0.35
Accounts Payable	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Total Current Liabilities	0.06	0.08	0.07	0.07	0.05	0.04	0.04	0.04	0.03
Total Non-current Liabilities*	0.35	0.31	0.31	0.31	0.30	0.28	0.28	0.19	0.02
Total Liabilities	0.42	0.40	0.37	0.38	0.35	0.33	0.32	0.23	0.05
Retained Earnings	(1.46)	(1.30)	(1.22)	(1.17)	(1.07)	(0.99)	(0.93)	(0.80)	(0.41)
Total Stockholder Equity	0.11	0.27	0.35	0.37	0.48	0.53	0.58	0.18	0.30

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q1 2021
Total Revenue	26.22	24.29	21.19	20.92	8.98	0.03	0.00	0.00	--	--	--	0.27
Cost of Revenue*	24.57	25.33	28.64	24.45	17.95	11.39	0.00	0.00	--	--	--	--
Gross Profit	1.65	(1.04)	(7.45)	(3.52)	(8.97)	(11.36)	0.00	0.00	10.09	--	--	--
Research & Development	21.21	35.63	27.89	27.43	26.73	30.83	40.32	36.61	30.67	25.16	37.24	30.73
Selling, General & Admin	39.95	35.80	36.28	30.27	29.53	33.68	27.33	21.90	18.18	15.73	10.61	8.74
Total Operating Expenses	61.16	71.43	64.17	57.70	56.27	64.51	67.88	58.93	48.85	--	--	--
Operating Income	(59.51)	(72.47)	(71.62)	(61.22)	(65.24)	(75.86)	(67.88)	(58.93)	(38.76)	(40.89)	(47.82)	(39.87)
Interest Expense	11.12	22.84	10.52	(6.83)	10.14	(30.83)	10.69	10.17	19.27	30.13	5.01	--
Pretax Income	(70.73)	(91.51)	(78.59)	(47.52)	(67.94)	(26.14)	(82.07)	(58.22)	(52.70)	(64.81)	(50.79)	(38.99)
Tax Provision	0.86	(1.18)	0.53	0.40	2.23	1.46	0.02	0.05	(0.01)	12.36	(4.94)	(5.72)
Net Income	(71.60)	(90.33)	(79.12)	(47.92)	(70.16)	(27.61)	(82.09)	(58.27)	(52.69)	(77.17)	(45.85)	(33.27)
Basic EPS	(0.27)	(0.34)	(0.30)	(0.18)	(0.26)	(0.09)	(0.31)	(0.22)	(0.24)	(0.45)	(0.26)	--
Diluted EPS	(0.27)	(0.34)	(0.30)	(0.18)	(0.26)	(0.09)	(0.31)	(0.22)	(0.24)	(0.45)	(0.26)	--

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q1 2021
Operating Cash Flow	(65.32)	(67.32)	(67.90)	(72.78)	(75.56)	(37.93)	(76.74)	(51.08)	(40.51)	(24.83)	(120.75)	(37.34)
Capital Expenditures	2.69	(0.88)	4.41	7.28	8.24	11.11	9.59	0.84	0.53	1.48	9.51	1.90
Free Cash Flow*	(68.00)	(66.44)	(72.31)	(80.06)	(83.81)	(49.05)	(86.33)	(51.92)	(41.05)	(26.31)	(130.26)	(39.24)
Investing Cash Flow	96.15	86.54	35.55	95.92	(59.55)	(383.59)	(9.59)	(0.84)	(0.53)	(1.48)	(9.51)	(1.90)
Financing Cash Flow	(2.06)	(1.80)	(1.77)	(0.77)	0.00	30.01	0.19	(2.08)	561.44	0.02	(0.91)	123.32

* Derived from reported values